JP7373869B2 - Oral composition - Google Patents
Oral composition Download PDFInfo
- Publication number
- JP7373869B2 JP7373869B2 JP2022100942A JP2022100942A JP7373869B2 JP 7373869 B2 JP7373869 B2 JP 7373869B2 JP 2022100942 A JP2022100942 A JP 2022100942A JP 2022100942 A JP2022100942 A JP 2022100942A JP 7373869 B2 JP7373869 B2 JP 7373869B2
- Authority
- JP
- Japan
- Prior art keywords
- muscle
- present
- acid
- tablets
- obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 60
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 claims description 76
- 150000003839 salts Chemical class 0.000 claims description 31
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims description 12
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims description 12
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims description 12
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims description 12
- 229940100243 oleanolic acid Drugs 0.000 claims description 12
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 9
- 230000003213 activating effect Effects 0.000 claims description 3
- 102000016942 Elastin Human genes 0.000 claims 1
- 108010014258 Elastin Proteins 0.000 claims 1
- 229920002549 elastin Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 description 59
- 239000003826 tablet Substances 0.000 description 53
- 230000003579 anti-obesity Effects 0.000 description 40
- 235000007586 terpenes Nutrition 0.000 description 32
- 210000003205 muscle Anatomy 0.000 description 30
- 150000003505 terpenes Chemical class 0.000 description 30
- 239000004615 ingredient Substances 0.000 description 19
- FRWNAQDBODEVAL-VMPITWQZSA-N (5e)-5-[(4-nitrophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\1C(=O)NC(=S)S/1 FRWNAQDBODEVAL-VMPITWQZSA-N 0.000 description 16
- QNMKGMUGYVWVFQ-UHFFFAOYSA-N 2alpha-Hydroxyursolic acid Natural products CC12CC(O)C(O)C(C)(C)C1CCC1(C)C2CC=C2C3C(C)C(C)(C)CCC3(C(O)=O)CCC21C QNMKGMUGYVWVFQ-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000005728 strengthening Methods 0.000 description 14
- 239000002775 capsule Substances 0.000 description 13
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 11
- 239000007910 chewable tablet Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 150000003648 triterpenes Chemical class 0.000 description 11
- 229940096998 ursolic acid Drugs 0.000 description 11
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 11
- -1 polycyclic triterpene Chemical class 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 206010049565 Muscle fatigue Diseases 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 229940068682 chewable tablet Drugs 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 4
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 4
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000004243 Tubulin Human genes 0.000 description 4
- 108090000704 Tubulin Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 4
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 4
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 244000144725 Amygdalus communis Species 0.000 description 3
- 235000017788 Cydonia oblonga Nutrition 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 3
- 244000061508 Eriobotrya japonica Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 235000004347 Perilla Nutrition 0.000 description 3
- 244000124853 Perilla frutescens Species 0.000 description 3
- 235000020224 almond Nutrition 0.000 description 3
- 208000036815 beta tubulin Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 2
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 2
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 description 2
- 240000000171 Crataegus monogyna Species 0.000 description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 244000062730 Melissa officinalis Species 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 235000010676 Ocimum basilicum Nutrition 0.000 description 2
- 240000007926 Ocimum gratissimum Species 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 244000141353 Prunus domestica Species 0.000 description 2
- 241000508269 Psidium Species 0.000 description 2
- 235000014360 Punica granatum Nutrition 0.000 description 2
- 244000294611 Punica granatum Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 244000178231 Rosmarinus officinalis Species 0.000 description 2
- 240000007651 Rubus glaucus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 240000000851 Vaccinium corymbosum Species 0.000 description 2
- 240000001717 Vaccinium macrocarpon Species 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- WLJUMPWVUPNXMF-UHFFFAOYSA-L calcium;3-hydroxy-3-methylbutanoate Chemical compound [Ca+2].CC(C)(O)CC([O-])=O.CC(C)(O)CC([O-])=O WLJUMPWVUPNXMF-UHFFFAOYSA-L 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000001916 dieting Nutrition 0.000 description 2
- 230000037228 dieting effect Effects 0.000 description 2
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 125000000567 diterpene group Chemical group 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940058690 lanosterol Drugs 0.000 description 2
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 150000002773 monoterpene derivatives Chemical class 0.000 description 2
- 235000002577 monoterpenes Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000021013 raspberries Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 150000003535 tetraterpenes Chemical class 0.000 description 2
- 235000009657 tetraterpenes Nutrition 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- IBFXLTFIVWRUQC-OVGYCKTGSA-N 9b,10b-epoxyroridin d Chemical compound C([C@@]12[C@]3(C)[C@H]4C[C@H]1OC1C5OC5(C)CCC13COC(=O)C1O[C@@]1(C)CCOC(\C=C\C=C/C(=O)O4)C(O)C)O2 IBFXLTFIVWRUQC-OVGYCKTGSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- QQXDYWHKPKEBJU-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCC[Na] Chemical compound CCCCCCCCCCCCCCCCCC[Na] QQXDYWHKPKEBJU-UHFFFAOYSA-N 0.000 description 1
- DNJVYWXIDISQRD-UHFFFAOYSA-N Cafestol Natural products C1CC2(CC3(CO)O)CC3CCC2C2(C)C1C(C=CO1)=C1CC2 DNJVYWXIDISQRD-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 241000723267 Diospyros Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- QFVOYBUQQBFCRH-UHFFFAOYSA-N Steviol Natural products C1CC2(C3)CC(=C)C3(O)CCC2C2(C)C1C(C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 244000003892 Vaccinium erythrocarpum Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241001247821 Ziziphus Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- DNJVYWXIDISQRD-JTSSGKSMSA-N cafestol Chemical compound C([C@H]1C[C@]2(C[C@@]1(CO)O)CC1)C[C@H]2[C@@]2(C)[C@H]1C(C=CO1)=C1CC2 DNJVYWXIDISQRD-JTSSGKSMSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000021019 cranberries Nutrition 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- PGZIKUPSQINGKT-UHFFFAOYSA-N dialuminum;dioxido(oxo)silane Chemical compound [Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O PGZIKUPSQINGKT-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- QFVOYBUQQBFCRH-VQSWZGCSSA-N steviol Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-VQSWZGCSSA-N 0.000 description 1
- 229940032084 steviol Drugs 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Description
本発明は、３－ヒドロキシ－３－メチル酪酸又はその塩及びテルペンを含有する経口組成物に関する。 The present invention relates to an oral composition containing 3-hydroxy-3-methylbutyric acid or a salt thereof and a terpene.
３－ヒドロキシ－３－メチル酪酸（ＨＭＢ）は、必須アミノ酸であるロイシンの代謝生成物であり、筋肉の合成促進や分解抑制にかかわっていることが知られている。しかしながら、体内でのＨＭＢ生成量は非常に少ないため、このＨＭＢをサプリメント等として摂取する試みがなされている。 3-Hydroxy-3-methylbutyric acid (HMB) is a metabolic product of the essential amino acid leucine, and is known to be involved in promoting muscle synthesis and inhibiting muscle breakdown. However, since the amount of HMB produced in the body is very small, attempts have been made to ingest this HMB as a supplement or the like.
このようなサプリメントに関し、３－ヒドロキシ－３－メチル酪酸カルシウム及び結晶セルロースを含有する錠剤が提案されている（特許文献１参照）。この特許文献１では、結晶セルロースを用いることにより打錠性を改善し、表面に凹凸のない錠剤を得ている。 Regarding such supplements, tablets containing calcium 3-hydroxy-3-methylbutyrate and crystalline cellulose have been proposed (see Patent Document 1). In Patent Document 1, tableting properties are improved by using crystalline cellulose, and tablets without irregularities on the surface are obtained.
上記のように、ＨＭＢに関する検討はなされているが、ＨＭＢと他成分との効果に関する検討はあまりなされていない。 As mentioned above, although studies have been made regarding HMB, there have been few studies regarding the effects of HMB and other components.
本発明の課題は、優れた筋肉増強効果、及び抗肥満効果を示す経口組成物を提供することにある。 An object of the present invention is to provide an oral composition that exhibits excellent muscle-building and anti-obesity effects.
本発明者らは、上記課題を解決すべく鋭意検討した結果、ＨＭＢ又はその塩と共に、テルペンを用いることにより、優れた筋肉増強効果、抗肥満効果を示すことを見いだし、本発明を完成するに至った。 As a result of intensive studies to solve the above problems, the present inventors discovered that the use of a terpene together with HMB or its salt exhibits an excellent muscle-building effect and anti-obesity effect, and has completed the present invention. It's arrived.
すなわち、本発明は、以下のとおりのものである。
＜１＞３－ヒドロキシ－３－メチル酪酸又はその塩、及びテルペンを含有することを特徴とする経口組成物。
＜２＞テルペンが、トリテルペンである＜１＞に記載の経口組成物。
＜３＞トリテルペンが、多環性トリテルペンである、＜２＞に記載の経口組成物。
＜４＞多環トリテルペンが、五環性トリテルペンである、＜３＞に記載の経口組成物。
＜５＞五環性トリテルペンが、ウルソール酸、マスリン酸、コロソリン酸、ベツリン酸、オレアノール酸のいずれかである、＜４＞に記載の経口組成物。
＜６＞筋肉増強用であることを特徴とする＜１＞～＜５＞のいずれかに記載の経口組成物。
＜７＞抗肥満用であることを特徴とする＜１＞～＜５＞に記載の経口組成物。
＜８＞３－ヒドロキシ－３－メチル酪酸又はその塩が、３－ヒドロキシ－３－メチル酪酸カルシウムであることを特徴とする＜１＞～＜７＞に記載の経口組成物。
＜９＞錠剤、カプセル剤、丸剤又はチュアブル錠剤のいずれかであることを特徴とする＜１＞～＜８＞のいずれか記載の経口組成物。
That is, the present invention is as follows.
<1> An oral composition containing 3-hydroxy-3-methylbutyric acid or a salt thereof and a terpene.
<2> The oral composition according to <1>, wherein the terpene is a triterpene.
<3> The oral composition according to <2>, wherein the triterpene is a polycyclic triterpene.
<4> The oral composition according to <3>, wherein the polycyclic triterpene is a pentacyclic triterpene.
<5> The oral composition according to <4>, wherein the pentacyclic triterpene is any one of ursolic acid, maslinic acid, corosolic acid, betulinic acid, and oleanolic acid.
<6> The oral composition according to any one of <1> to <5>, which is used for muscle strengthening.
<7> The oral composition according to <1> to <5>, which is used for anti-obesity.
<8> The oral composition according to <1> to <7>, wherein the 3-hydroxy-3-methylbutyric acid or its salt is calcium 3-hydroxy-3-methylbutyrate.
<9> The oral composition according to any one of <1> to <8>, which is in the form of a tablet, capsule, pill, or chewable tablet.
本発明によれば、優れた筋肉増強効果、抗肥満効果を示す経口組成物を提供することができる。特に、本発明によれば、運動と併用することで、より優れた筋肉増強効果、抗肥満効果を示す経口組成物を提供することができる。 According to the present invention, it is possible to provide an oral composition that exhibits excellent muscle-building effects and anti-obesity effects. In particular, according to the present invention, it is possible to provide an oral composition that exhibits superior muscle-building effects and anti-obesity effects when used in conjunction with exercise.
本発明の経口組成物は、３－ヒドロキシ－３－メチル酪酸又はその塩と、テルペンとを含有することを特徴とする。 The oral composition of the present invention is characterized by containing 3-hydroxy-3-methylbutyric acid or a salt thereof and a terpene.
３－ヒドロキシ－３－メチル酪酸又はその塩と共にテルペンを用いることにより、筋肉増強効果や筋肉疲労回復（筋肉疲労改善）効果を向上させることができ、シェイプアップや、スポーツ選手の筋肉増強、病後の筋力回復、高齢者の寝たきり防止、運動時の筋肉ダメージの抑制、運動後の筋肉疲労回復、基礎代謝の向上等に用いることができる。 By using terpenes together with 3-hydroxy-3-methylbutyric acid or its salts, it is possible to improve the muscle strengthening effect and muscle fatigue recovery (muscle fatigue improvement) effect, and it is useful for shaping up, muscle building for athletes, and post-illness. It can be used for muscle recovery, prevention of bedriddenness in the elderly, suppression of muscle damage during exercise, recovery from muscle fatigue after exercise, improvement of basal metabolism, etc.
さらに、３－ヒドロキシ－３－メチル酪酸又はその塩と共にテルペンを用いることにより、肥満を抑制することができる。すなわち、本発明の経口組成物は、抗肥満、体脂肪の低減、体脂肪の蓄積抑制、ダイエット等に用いることができる。 Furthermore, obesity can be suppressed by using a terpene together with 3-hydroxy-3-methylbutyric acid or a salt thereof. That is, the oral composition of the present invention can be used for anti-obesity, reduction of body fat, inhibition of body fat accumulation, dieting, and the like.
［３－ヒドロキシ－３－メチル酪酸又はその塩］
３－ヒドロキシ－３－メチル酪酸（ＨＭＢ）とは、必須アミノ酸であるロイシンの代謝産物であり、ヒトの体内で合成される。本発明においては、ＨＭＢ又はその塩が使用できる。ＨＭＢの塩としては、特に制限されないが、カルシウム塩、ナトリウム塩、カリウム塩、マグネシウム塩が挙げられ、筋肉増強効果や抗肥満効果の観点から、カルシウム塩（ＨＭＢＣａ）が好ましい。本発明の経口組成物におけるＨＭＢ又はその塩は、公知の方法により合成したものや、市販品を用いることができる。市販品としては、食品に適用可能なものであれば限定されない。また、本発明においてＨＭＢ又はその塩は１種類のみを使用しても良いし、２種類以上を使用しても良い。
[3-hydroxy-3-methylbutyric acid or its salt]
3-Hydroxy-3-methylbutyric acid (HMB) is a metabolite of leucine, an essential amino acid, and is synthesized in the human body. In the present invention, HMB or a salt thereof can be used. Salts of HMB include, but are not particularly limited to, calcium salts, sodium salts, potassium salts, and magnesium salts, with calcium salts (HMBCa) being preferred from the viewpoint of muscle-building effects and anti-obesity effects. HMB or a salt thereof in the oral composition of the present invention can be synthesized by a known method or a commercially available product. Commercially available products are not limited as long as they are applicable to foods. Moreover, in the present invention, only one type of HMB or its salt may be used, or two or more types may be used.
３－ヒドロキシ－３－メチル酪酸又はその塩の含有量は、筋肉増強効果及び／又は抗肥満効果が認められる量であれば特に限定されないが、例えば、組成物全量に対して０．１～９９質量％であり、好ましくは１～９８質量％、より好ましくは５～９７質量％である。 The content of 3-hydroxy-3-methylbutyric acid or its salt is not particularly limited as long as it has a muscle-building effect and/or an anti-obesity effect, but for example, it is 0.1 to 99% of the total amount of the composition. % by mass, preferably 1 to 98% by mass, more preferably 5 to 97% by mass.
［テルペン］
テルペンとは、イソプレンを構成単位とする炭化水素で、植物や昆虫、菌類などによって作り出される生体物質である。テルペンのうち、カルボニル基やヒドロキシ基などの官能基を持つ誘導体はテルペノイドと呼ばれる。本発明において使用されるテルペンとしては、例えば、ヘミテルペン、モノテルペン、セスキテルペン、ジテルペン、トリテルペン、テトラテルペンが挙げられる。また、本発明においては、非環式、単環式、多環式のいずれのテルペンも使用できる。また、本発明においてテルペンは１種類のみを使用しても良いし、２種類以上を使用しても良い。
[Terpene]
Terpenes are hydrocarbons whose constituent unit is isoprene, and are biological substances produced by plants, insects, fungi, etc. Among terpenes, derivatives with functional groups such as carbonyl groups and hydroxyl groups are called terpenoids. Terpenes used in the present invention include, for example, hemiterpenes, monoterpenes, sesquiterpenes, diterpenes, triterpenes, and tetraterpenes. Further, in the present invention, any acyclic, monocyclic, or polycyclic terpene can be used. Moreover, in the present invention, only one type of terpene may be used, or two or more types of terpene may be used.
本発明において使用できるテルペンの具体例としては、例えば、リナロール、リモネン、カフェストール、ステビオール、コロソリン酸、ウルソール酸、オレアノール酸、マスリン酸、ベツリン酸、スクアレン、ラノステロール、β-カロテン、リコペンが挙げられる。 Specific examples of terpenes that can be used in the present invention include linalool, limonene, cafestol, steviol, corosolic acid, ursolic acid, oleanolic acid, maslinic acid, betulinic acid, squalene, lanosterol, β-carotene, and lycopene. .
本発明においては、モノテルペン、ジテルペン、トリテルペン、テトラテルペンが好ましく、ＨＭＢ又はその塩と併用することにより、優れた筋肉増強効果、抗肥満効果が得られる観点から、トリテルペンがより好ましい。また、環式のテルペンが好ましく、本発明においては、ＨＭＢ又はその塩と併用することにより、優れた筋肉増強効果、抗肥満効果が得られる観点から、多環式のテルペンがより好ましい。 In the present invention, monoterpenes, diterpenes, triterpenes, and tetraterpenes are preferred, and triterpenes are more preferred from the viewpoint of obtaining excellent muscle-strengthening effects and anti-obesity effects when used in combination with HMB or a salt thereof. Further, cyclic terpenes are preferable, and in the present invention, polycyclic terpenes are more preferable from the viewpoint of obtaining excellent muscle-strengthening effects and anti-obesity effects when used in combination with HMB or a salt thereof.
これらの観点から、本発明において使用できるテルペンのうち、好ましくは、多環式のトリテルペンであり、より好ましくは五環性トリテルペンであり、特に好ましくは、コロソリン酸、ウルソール酸、オレアノール酸、マスリン酸、ベツリン酸、スクアレン、ラノステロールであり、より好ましくはコロソリン酸、ウルソール酸、オレアノール酸、マスリン酸、ベツリン酸である。本発明においては、植物から抽出や精製により得られるものや、化学合成により得られるものを使用できる。 From these viewpoints, among the terpenes that can be used in the present invention, polycyclic triterpenes are preferred, pentacyclic triterpenes are more preferred, and corosolic acid, ursolic acid, oleanolic acid, and maslinic acid are particularly preferred. , betulinic acid, squalene, and lanosterol, and more preferably corosolic acid, ursolic acid, oleanolic acid, maslinic acid, and betulinic acid. In the present invention, those obtained by extraction or purification from plants or those obtained by chemical synthesis can be used.
植物由来のテルペンを使用する場合、植物加工物におけるテルペンの含有量は、通常知られているテルペンの分析法のうち測定試料の状況に適した分析法により測定することができる。例えば、液体クロマトグラフィー法で分析することが可能である。なお、測定の際には装置の分離能に適合させるため試料中の夾雑物を除去したりする等、必要に応じて適宜処理を施してもよい。 When using plant-derived terpenes, the content of terpenes in the processed plant product can be measured by an analysis method suitable for the situation of the measurement sample among commonly known terpene analysis methods. For example, it is possible to analyze by liquid chromatography. Note that during measurement, appropriate processing may be performed as necessary, such as removing impurities from the sample in order to match the separation ability of the apparatus.
［コロソリン酸］
コロソリン酸はトリテルペンの一種であり、以下の構造式（１）で表される。
[Corosolic acid]
Corosolic acid is a type of triterpene and is represented by the following structural formula (1).
コロソリン酸は、カリン、アーモンド、バナバ、クランベリー、ビワ、シソ等に含まれることが知られている。本発明においては、これらの植物より抽出したものや精製したもの、化学合成によって得られたものを使用することができる。 Corosolic acid is known to be contained in quince, almond, banaba, cranberry, loquat, perilla, etc. In the present invention, those extracted from these plants, those purified, and those obtained by chemical synthesis can be used.
コロソリン酸の含有量は、ＨＭＢ又はその塩と併用することにより筋肉増強効果及び／又は抗肥満効果が認められる量であれば特に限定されないが、例えば、組成物全量に対して０．０００１～２０質量％であり、好ましくは０．００１～１０質量％、より好ましくは０．００５～５質量％である。 The content of corosolic acid is not particularly limited as long as the muscle-building effect and/or anti-obesity effect is observed when used in combination with HMB or its salt, but for example, the content of corosolic acid is 0.0001 to 20% based on the total amount of the composition. % by mass, preferably 0.001 to 10% by mass, more preferably 0.005 to 5% by mass.
［ウルソール酸］
ウルソール酸はトリテルペンの一種であり、以下の構造式（２）で表される。
[Ursolic acid]
Ursolic acid is a type of triterpene and is represented by the following structural formula (2).
ウルソール酸は、オリーブ葉、アーモンド、リンゴ、クランベリー、サンザシ、ラズベリー、カリン、ローズマリー葉、グァバ、シソ葉、ブルーベリー、プルーン、ビワ、ザクロ、レモンバーム、バジル、ローズヒップ、カキ、センブリ、クマコケモモ等に含まれることが知られている。本発明においては、これらの植物より抽出したものや精製したもの、化学合成によって得られたものを使用することができる。 Ursolic acid is found in olive leaves, almonds, apples, cranberries, hawthorn, raspberries, quince, rosemary leaves, guava, perilla leaves, blueberries, prunes, loquats, pomegranates, lemon balm, basil, rosehips, persimmons, Japanese aspens, bearberry, etc. known to be included. In the present invention, those extracted from these plants, those purified, and those obtained by chemical synthesis can be used.
ウルソール酸の含有量は、ＨＭＢ又はその塩と併用することにより筋肉増強効果及び／又は抗肥満効果が認められる量であれば特に限定されないが、例えば、組成物全量に対して０．０００１～２０質量％であり、好ましくは０．００１～１０質量％、より好ましくは０．００５～５質量％である。 The content of ursolic acid is not particularly limited as long as the muscle-building effect and/or anti-obesity effect is observed when used in combination with HMB or its salt, but for example, the content of ursolic acid is 0.0001 to 20% based on the total amount of the composition. % by mass, preferably 0.001 to 10% by mass, more preferably 0.005 to 5% by mass.
［オレアノール酸］
オレアノール酸はトリテルペンの一種であり、以下の構造式（３）で表される。
[Oleanolic acid]
Oleanolic acid is a type of triterpene and is represented by the following structural formula (3).
オレアノール酸は、オリーブ果実及び葉、ブドウ、ビート、ナツメ、アーモンド、バナバ葉、セージ、サンザシ、ラズベリー、カリン、ローズマリー葉、グァバ、シソ葉、ブルーベリー、プルーン、ビワ、ザクロ、レモンバーム、バジル、ローズヒップ、カキ、センブリ等に含まれることが知られている。本発明においては、これらの植物より抽出したものや精製したもの、化学合成によって得られたものを使用することができる。 Oleanolic acid is found in olive fruits and leaves, grapes, beets, jujubes, almonds, banaba leaves, sage, hawthorn, raspberries, quince, rosemary leaves, guava, perilla leaves, blueberries, prunes, loquats, pomegranates, lemon balm, basil, rose. It is known to be contained in hips, oysters, Japanese cabbage, etc. In the present invention, those extracted from these plants, those purified, and those obtained by chemical synthesis can be used.
オレアノール酸の含有量は、ＨＭＢ又はその塩と併用することにより筋肉増強効果及び／又は抗肥満効果が認められる量であれば特に限定されないが、例えば、組成物全量に対して０．０００１～２０質量％であり、好ましくは０．００１～１０質量％、より好ましくは０．００５～５質量％である。 The content of oleanolic acid is not particularly limited as long as the muscle-building effect and/or anti-obesity effect is observed when used in combination with HMB or its salt, but for example, 0.0001 to 20% of the total amount of the composition. % by mass, preferably 0.001 to 10% by mass, more preferably 0.005 to 5% by mass.
本発明の経口組成物は、例えば、医薬品（医薬部外品を含む）や、特定保健用食品、栄養機能食品、機能性表示食品等の所定機関より効能の表示が認められた機能性食品などのいわゆる健康食品や、一般的な食品、食品添加剤、飼料等として用いることができる。 The oral composition of the present invention can be used, for example, as a pharmaceutical (including quasi-drugs), as a food for specified health uses, as a food with nutritional function claims, as a functional food whose efficacy has been approved by a designated organization such as a food with functional claims. It can be used as so-called health foods, general foods, food additives, feeds, etc.
本発明の経口組成物は、筋肉の増強のために用いられる筋肉増強用組成物として用いることができる。かかる筋肉増強用組成物としては、ＨＭＢ又はその塩及びテルペンを含有し、筋肉増強や筋肉疲労回復に用いられる点において、製品として他の製品と区別することができるものであれば特に制限されるものではなく、例えば、本発明に係る製品の本体、包装、説明書、宣伝物のいずれかに筋肉増強、筋合成の亢進、筋分解の抑制、筋肉量（筋肉重量、筋断面積、筋肉密度）の低下抑制・維持・増加、筋肉の質の低下抑制・維持・向上、筋力（パワー、持久力）の低下抑制・維持・増加、運動能力の低下抑制・維持・向上、代謝（基礎代謝、安静時及び運動時代謝）の低下抑制・維持・向上、除脂肪体重の低下抑制・維持・増加、筋肉疲労の予防・改善、筋肉増強による代謝向上効果、ロコモティブシンドロームの予防・改善効果、サルコペニアの予防・改善効果の機能がある旨を表示したものが本発明の範囲に含まれる。なお、本発明の筋肉増強用組成物は、製品の包装等に、本発明における組合せの成分（ＨＭＢ又はその塩及びテルペン）が筋肉増強の有効成分として表示されているものに限られない。例えば、有効成分を特定していないものであってもよく、ＨＭＢ又はその塩のみを有効成分として表示したものであってもよく、テルペンのみを有効成分として表示したものであってもよい。 The oral composition of the present invention can be used as a muscle-building composition used for muscle building. Such muscle-strengthening compositions are particularly limited as long as they contain HMB or its salts and terpenes, and can be distinguished from other products in that they are used for muscle-strengthening and recovery from muscle fatigue. For example, muscle building, promotion of muscle synthesis, inhibition of muscle breakdown, muscle mass (muscle weight, muscle cross-sectional area, muscle density) may be included in the main body, packaging, instruction manual, or promotional material of the product according to the present invention. ), suppressing, maintaining, and increasing the decline in muscle quality, suppressing, maintaining, and increasing the decline in muscle strength (power, endurance), suppressing, maintaining, and increasing the decline in athletic ability, metabolism (basal metabolism, Suppressing/maintaining/improving decline in (metabolism at rest and during exercise); Suppressing/maintaining/increasing lean body mass; Preventing/improving muscle fatigue; Improving metabolism through muscle building; Preventing/improving locomotive syndrome; Preventing sarcopenia. The scope of the present invention includes products that indicate that they have preventive and ameliorative functions. In addition, the muscle-strengthening composition of the present invention is not limited to one in which the combined ingredients (HMB or its salt and terpene) of the present invention are displayed as an active ingredient for muscle-strengthening on the product packaging or the like. For example, the active ingredient may not be specified, only HMB or its salt may be indicated as the active ingredient, or only terpene may be indicated as the active ingredient.
具体的に、本発明の筋肉増強用組成物としては、医薬品（医薬部外品を含む）やいわゆる健康食品が挙げられ、いわゆる健康食品においては、「筋肉をつくる力をサポートする」、「筋肉の分解を抑える」、「筋力を増強する」、「歩行能力の低下抑制・維持・改善・向上」、「筋肉増強による代謝向上を図る」、「代謝の衰えを抑える」、「筋肉疲労の予防・回復」、「バランス能力の低下抑制・維持」、「シェイプアップ」、「マッチョ」、「細マッチョ」、「美ボディ」、「寝たきり予防」、「転倒予防」、「筋肉増強による代謝向上を図る」、「筋肉量や筋力を維持する」等を表示したものを例示することができる。本発明の経口組成物を摂取する対象としては、筋肉の増強を必要とする人であれば特に限定されないが、シェイプアップを目的とする人や、スポーツ選手や、足腰の弱った高齢者等を好ましく例示することができる。 Specifically, the muscle-building composition of the present invention includes pharmaceuticals (including quasi-drugs) and so-called health foods. ``Suppress the breakdown of metabolism'', ``Increase muscle strength'', ``Suppress decline in walking ability, maintain, improve and improve'', ``Improve metabolism by strengthening muscles'', ``Suppress metabolic decline'', ``Prevent muscle fatigue''.・Recovery", "Suppression and maintenance of loss of balance ability", "Shape up", "Macho", "Slim macho", "Beautiful body", "Bedridden prevention", "Fall prevention", "Improve metabolism through muscle strengthening" For example, it may display messages such as "Aim for", "Maintain muscle mass and strength", etc. The subjects who take the oral composition of the present invention are not particularly limited as long as they need to strengthen their muscles, but include people who want to get in shape, athletes, and elderly people with weak legs. Preferred examples can be given.
また、本発明の経口組成物は、抗肥満のために用いられる抗肥満用組成物として用いることができる。かかる抗肥満用組成物としては、ＨＭＢ又はその塩及びテルペンを含有し、抗肥満（肥満抑制）に用いられる点において、製品として他の製品と区別することができるものであれば特に制限されるものではなく、例えば、本発明に係る製品の本体、包装、説明書、宣伝物のいずれかに、抗肥満（ダイエット、体脂肪低減、体脂肪蓄積抑制、メタボリックシンドローム改善、痩身などを含む）の機能がある旨を表示したものが本発明の範囲に含まれる。なお、本発明の抗肥満用組成物は、製品の包装等に、本発明における組合せの成分（ＨＭＢ又はその塩及びテルペン）が抗肥満の有効成分として表示されているものに限られない。例えば、有効成分を特定していないものであってもよく、ＨＭＢ又はその塩のみを有効成分として表示したものであってもよく、テルペンのみを有効成分として表示したものであってもよい。 Moreover, the oral composition of the present invention can be used as an anti-obesity composition used for anti-obesity. Such anti-obesity compositions are particularly limited as long as they contain HMB or a salt thereof and a terpene and can be distinguished from other products in terms of their use in anti-obesity (obesity suppression). For example, the product according to the present invention may contain anti-obesity (including dieting, body fat reduction, body fat accumulation suppression, metabolic syndrome improvement, slimming, etc.) content on the main body, packaging, instruction manual, or advertising material of the product according to the present invention. Items that indicate that they have a function are included within the scope of the present invention. The anti-obesity composition of the present invention is not limited to one in which the combination of ingredients (HMB or its salt and terpene) of the present invention is indicated as an anti-obesity active ingredient on the product packaging or the like. For example, the active ingredient may not be specified, only HMB or its salt may be indicated as the active ingredient, or only terpene may be indicated as the active ingredient.
具体的に、本発明の抗肥満用組成物としては、医薬品（医薬部外品を含む）やいわゆる健康食品が挙げられ、いわゆる健康食品においては、「体脂肪が気になる方へ」、「肥満気味な方へ」、「体重（ＢＭＩ）が気になる方へ」、「体重やお腹の脂肪（内臓脂肪と皮下脂肪）を減らす」、「ウエスト周囲長を減らす」等を表示したものを例示することができる。 Specifically, the anti-obesity composition of the present invention includes pharmaceuticals (including quasi-drugs) and so-called health foods. ``For those who are overweight'', ``For those who are concerned about their body weight (BMI)'', ``Reduce weight and belly fat (visceral fat and subcutaneous fat)'', ``Reduce waist circumference'', etc. I can give an example.
本発明の経口組成物による筋肉増強効果、抗肥満効果は、日常生活を送る上で本発明の組成物を摂取すれば得られるものであるが、運動と併用することで、より優れた効果を得ることができる。ここで言う運動とは、有酸素運動又はレジスタンス運動（筋力トレーニング、ウェイトトレーニング）のいずれか一種以上である。特に、本発明の経口組成物による筋肉増強効果を得る場合、本発明の経口組成物と併用する運動の種類は特に制限はないが、有酸素運動、レジスタンス運動のうちいずれか一種以上を実施することが好ましく、レジスタンス運動を実施することが特に好ましい。また、運動を実施する場合の運動量としては、１日あたり１０分以上、好ましくは２０分以上、より好ましくは３０分以上である。 The muscle-strengthening effect and anti-obesity effect of the oral composition of the present invention can be obtained by ingesting the composition of the present invention in daily life, but even better effects can be obtained by taking it in conjunction with exercise. Obtainable. Exercise here means one or more types of aerobic exercise or resistance exercise (strength training, weight training). In particular, when obtaining the muscle-strengthening effect of the oral composition of the present invention, there is no particular restriction on the type of exercise used in combination with the oral composition of the present invention, but one or more of aerobic exercise and resistance exercise may be performed. It is particularly preferred to carry out resistance exercise. In addition, the amount of exercise when exercising is 10 minutes or more, preferably 20 minutes or more, and more preferably 30 minutes or more per day.
本発明の組成物の形態としては、例えば、錠状、カプセル状、粉末状、顆粒状、液状、粒状、棒状、板状、ブロック状、固形状、丸状、ペースト状、クリーム状、カプレット状、ゲル状、チュアブル錠状、スティック状等を挙げることができる。これらの中でも、錠状、カプセル状、粉末状、顆粒状、丸状、チュアブル錠状の形態が好ましく、錠状、カプセル状、丸状、チュアブル錠状がより好ましい。 Examples of the form of the composition of the present invention include tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, solids, rounds, pastes, creams, and caplets. , gel form, chewable tablet form, stick form, etc. Among these, tablet, capsule, powder, granule, round, and chewable tablet forms are preferred, and tablet, capsule, round, and chewable tablet forms are more preferred.
本発明の組成物を錠状、丸状、チュアブル錠状とする場合、賦形剤、滑沢剤、流動化剤のいずれか一種以上を添加することにより、成型性を高めるとともに得られた錠剤、丸剤又はチュアブル錠剤の保存安定性を向上するため、好ましい。特に、賦形剤及び滑沢剤を使用することで保存安定性をより高めることができる。 When the composition of the present invention is made into a tablet, a round shape, or a chewable tablet, one or more of excipients, lubricants, and fluidizing agents can be added to improve moldability and to make the resulting tablets , is preferred because it improves the storage stability of pills or chewable tablets. In particular, storage stability can be further enhanced by using excipients and lubricants.
賦形剤とは、組成物の取扱いあるいは成形の向上や服用を便利にするために加えるものである。本発明に使用できる賦形剤としては特に制限はなく、例えば、デンプン、アルファー化デンプン、部分アルファー化デンプン、デンプン分解物等のデンプン又はその誘導体、結晶セルロース、糖アルコール、乳糖、ビール酵母、低置換度ヒドロキシプロピルセルロース、ヒドロキシプロピルセルロース、精製白糖、軽質無水ケイ酸、ケイ酸カルシウム、酸化チタン、沈降炭酸カルシウム等などが挙げられる。これらは、１種単独で使用してもよいし、２種以上を併用してもよい。 Excipients are added to improve the handling or shaping of the composition or to make it more convenient to administer. There are no particular limitations on excipients that can be used in the present invention, and examples include starch, pregelatinized starch, partially pregelatinized starch, starch derivatives such as starch decomposition products, crystalline cellulose, sugar alcohols, lactose, brewer's yeast, Examples include substituted hydroxypropyl cellulose, hydroxypropyl cellulose, refined white sugar, light anhydrous silicic acid, calcium silicate, titanium oxide, precipitated calcium carbonate, and the like. These may be used alone or in combination of two or more.
滑沢剤とは、錠剤用の粉末を圧縮する際に打錠機杵臼と錠剤間の摩擦を緩和し、スティッキングなどの打錠障害を防ぐために使用するものである。本発明に使用できる滑沢剤としては、上記目的を達成することが可能な成分であれば特に制限はなく、例えば、ステアリン酸、ステアリン酸カルシウム、ステアリン酸マグネシウム等のステアリン酸又はその塩、フマル酸ステアリルナトリウム、ショ糖脂肪酸エステル、タルク、ポリエチレングリコール、植物油脂、硬化油などが挙げられる。これらは、１種単独で使用してもよく、２種以上を併用してもよい。 A lubricant is used to reduce friction between the tablet punch and die of a tablet when compressing powder for tablets, and to prevent tableting problems such as sticking. The lubricant that can be used in the present invention is not particularly limited as long as it is a component that can achieve the above purpose, and examples include stearic acid or its salts such as stearic acid, calcium stearate, and magnesium stearate, and fumaric acid. Examples include stearyl sodium, sucrose fatty acid ester, talc, polyethylene glycol, vegetable oil, and hydrogenated oil. These may be used alone or in combination of two or more.
流動化剤とは、混合末や顆粒の流動性を改善するために使用するものである。本発明に使用できる流動化剤としては特に制限はなく、例えば二酸化ケイ素、ケイ酸アルミニウム、ケイ酸アルミン酸マグネシウム、リン酸カルシウム、炭酸マグネシウム、酸化マグネシウムなどが挙げられる。これらは、１種単独で使用してもよいし、２種以上を併用してもよい。本発明において、賦形剤、滑沢剤、流動化剤はいずれも市販品を使用することができる。 A fluidizing agent is used to improve the fluidity of mixed powder or granules. The fluidizing agent that can be used in the present invention is not particularly limited, and examples include silicon dioxide, aluminum silicate, magnesium aluminate silicate, calcium phosphate, magnesium carbonate, and magnesium oxide. These may be used alone or in combination of two or more. In the present invention, commercially available excipients, lubricants, and fluidizing agents can all be used.
本発明の組成物におけるＨＭＢ又はその塩及びテルペン（以下、本発明の成分ともいう）の含有量としては、その効果の奏する範囲で適宜含有させればよい。 The content of HMB or a salt thereof and terpene (hereinafter also referred to as components of the present invention) in the composition of the present invention may be appropriately contained within a range where the effects thereof can be achieved.
具体的には、本発明の経口組成物が錠状、丸状、カプセル状のサプリメントや医薬品の場合には、本発明の成分が乾燥質量換算で全体の５～９９質量％含まれていることが好ましく、８～９８質量％含まれていることがより好ましく、１０～９７質量％含まれていることが特に好ましい。また、本発明の経口組成物がチュアブル錠状のサプリメントや医薬品の場合には、本発明の成分が乾燥質量換算で全体の０．１～７０質量％含まれていることが好ましく、０．５～６０質量％含まれていることがより好ましく、１～５０質量％含まれていることが特に好ましい。粉末状、顆粒状のサプリメントや医薬品の場合、本発明の成分が乾燥質量換算で全体の０．１～９０質量％含まれていることが好ましく、０．５～８０質量％含まれていることがより好ましく、１～７０質量％含まれていることが特に好ましい。液状のサプリメントや医薬品の場合、本発明の成分が乾燥質量換算で全体の５～９９質量％含まれていることが好ましく、８～９８質量％含まれていることがより好ましく、１０～９７質量％含まれていることが特に好ましい。 Specifically, when the oral composition of the present invention is a tablet, round, or capsule-shaped supplement or pharmaceutical, the component of the present invention must be contained in an amount of 5 to 99% by mass of the total in terms of dry mass. is preferred, more preferably 8 to 98% by mass, and particularly preferably 10 to 97% by mass. In addition, when the oral composition of the present invention is a chewable tablet-shaped supplement or medicine, it is preferable that the component of the present invention is contained in an amount of 0.1 to 70% by mass of the total in terms of dry mass, and 0.5% by mass. It is more preferable that the content is from 1 to 60% by mass, and particularly preferably from 1 to 50% by mass. In the case of powdered or granular supplements or pharmaceuticals, the component of the present invention preferably contains 0.1 to 90% by mass, and preferably 0.5 to 80% by mass, of the total dry mass. is more preferable, and it is particularly preferably contained in an amount of 1 to 70% by mass. In the case of liquid supplements and pharmaceuticals, the component of the present invention is preferably contained in an amount of 5 to 99% by weight, more preferably 8 to 98% by weight, and 10 to 97% by weight in terms of dry weight. It is particularly preferable that the content is %.
本発明の経口組成物の摂取量としては特に制限はないが、本発明の効果をより顕著に発揮させる観点から、成人の１日当たり、ＨＭＢ又はその塩の摂取量が、１００ｍｇ／日以上となるように摂取することが好ましく、２００ｍｇ／日以上となるように摂取することがより好ましく、３００ｍｇ／日以上となるように摂取することが特に好ましい。その上限は、例えば、１００００ｍｇ／日であり、好ましくは８０００ｍｇ／日であり、より好ましくは５０００ｍｇ／日である。また、成人の１日当たり、テルペンの摂取量が、０．００１ｍｇ／日以上となるように摂取することが好ましく、０．００５ｍｇ／日以上となるように摂取することがより好ましく、０．０１ｍｇ／日以上となるように摂取することが特に好ましい。その上限は、例えば、１００ｍｇ／日であり、好ましくは８０ｍｇ／日であり、より好ましくは５０ｍｇ／日である。本発明の経口組成物は、１日の摂取量が前記摂取量となるように適宜設計すればよく、１回で摂取しても良いし、複数回に分けて摂取しても良い。例えば、錠剤、カプセル剤、丸剤又はチュアブル錠剤の場合は１日あたり１～４回の摂取回数とし、合計量として前記摂取量が摂取できれば良く、飲料の場合、１日の摂取量に前記摂取量が配合されていれば良い。本発明の経口組成物は、１日の摂取量が前記摂取量となるように、１つの容器に、又は例えば２～３の複数の容器に分けて、１日分として収容することができる。 Although there is no particular restriction on the amount of the oral composition of the present invention to be ingested, from the viewpoint of more significantly exerting the effects of the present invention, the amount of HMB or its salt ingested per day by adults should be 100 mg/day or more. It is preferable to take in an amount of 200 mg/day or more, more preferably 200 mg/day or more, and particularly preferably 300 mg/day or more. The upper limit is, for example, 10,000 mg/day, preferably 8,000 mg/day, and more preferably 5,000 mg/day. In addition, it is preferable that the daily intake of terpenes for adults is 0.001 mg/day or more, more preferably 0.005 mg/day or more, and 0.01 mg/day. It is particularly preferable to take it for at least 1 day. The upper limit is, for example, 100 mg/day, preferably 80 mg/day, and more preferably 50 mg/day. The oral composition of the present invention may be appropriately designed so that the daily intake amount is the above-mentioned intake amount, and it may be ingested at one time or divided into multiple times. For example, in the case of tablets, capsules, pills, or chewable tablets, it is sufficient that the intake is 1 to 4 times per day, and the above intake can be taken as a total amount, and in the case of drinks, the intake should be added to the daily intake. It is good if the amount is mixed. The oral composition of the present invention can be stored in one container or divided into a plurality of containers, for example, 2 to 3, so that the daily intake amount is the above-mentioned intake amount.
ＨＭＢ又はその塩及びテルペンの配合質量比としては、乾燥質量換算で、１：０．００００１～１０の範囲であることが好ましく、１：０．００００５～５の範囲であることがより好ましく、１：０．０００１～１の範囲であることが特に好ましい。 The blending mass ratio of HMB or its salt and terpene is preferably in the range of 1:0.00001 to 10, more preferably in the range of 1:0.00005 to 5, in terms of dry mass. : The range of 0.0001 to 1 is particularly preferable.
本発明の組成物は、必要に応じて、本発明の成分以外の他の成分を添加して、公知の方法によって製造することができる。本発明の成分以外の他の成分としては、例えば、水溶性ビタミン（ビタミンＢ１、Ｂ２、Ｂ３、Ｂ５、Ｂ６、Ｂ１２、Ｂ１３、Ｂ１５、Ｂ１７、ビオチン、コリン、葉酸、イノシトール、ＰＡＢＡ、ビタミンＣ、ビタミンＰ）、油溶性ビタミン（ビタミンＡ、Ｄ、Ｅ、Ｋ）等のビタミン類；マグネシウム、リン、亜鉛、鉄等のミネラル類；タウリン、ニンニク等に含まれる含硫化合物；ヘスペリジン、ケルセチン等のフラバノイド或いはフラボノイド類；コラーゲン等のタンパク質；ペプチド；アミノ酸；動物性油脂；植物性油脂；動物・植物の粉砕物又は抽出物等を挙げることができる。特に、糖質を筋肉に運ぶことが可能なグルカゴン様ペプチド－１（ＧＬＰ－１）ホルモンの分泌を亢進する成分が好ましく、例えば、スピルリナ、甘藷茎葉、マジョラム、カワラヨモギが挙げられる。 The composition of the present invention can be manufactured by a known method by adding other components other than the components of the present invention, if necessary. Other ingredients other than the ingredients of the present invention include, for example, water-soluble vitamins (vitamins B1, B2, B3, B5, B6, B12, B13, B15, B17, biotin, choline, folic acid, inositol, PABA, vitamin C, Vitamins such as vitamin P) and oil-soluble vitamins (vitamins A, D, E, K); Minerals such as magnesium, phosphorus, zinc, iron; Sulfur-containing compounds contained in taurine, garlic, etc.; Hesperidin, quercetin, etc. Examples include flavanoids or flavonoids; proteins such as collagen; peptides; amino acids; animal oils; vegetable oils; ground products or extracts of animals and plants. Particularly preferred are ingredients that enhance the secretion of glucagon-like peptide-1 (GLP-1) hormone, which can transport carbohydrates to muscles, such as spirulina, sweet potato stems and leaves, marjoram, and mugwort.
以下、本発明を実施例に基づき説明する。 Hereinafter, the present invention will be explained based on examples.
試験１：筋管細胞賦活作用の評価
（１）３７℃、５％ＣＯ２インキュベーター内で、７５ｃｍ２フラスコを用いて、マウス筋芽細胞株（Ｃ２Ｃ１２）を１０％（Ｖ／Ｖ）ＦＢＳ含有ＤＭＥＭにて培養した。
（２）トリプシン処理により浮遊させた細胞を、７５ｃｍ２フラスコからコラーゲンコートした９６ウェルプレートの各ウェルに５０００ｃｅｌｌｓ／ｗｅｌｌの細胞密度で播種した。
（３）３７℃、５％ＣＯ２インキュベーター内でコンフルエントまで培養した後、分化誘導培地にて５日間培養した。
（４）０．５％（Ｖ／Ｖ）ＤＭＳＯ含有無血清ＤＭＥＭで所定濃度に調製した被験物質（表１～表３）を含有する培地を各１００μＬ添加し、２４時間培養した。
（５）培地を除去した後、各ウェルを無血清ＤＭＥＭ １５０μＬ／ｗｅｌｌで１回洗浄した。次いで、無血清ＤＭＥＭで３０倍に希釈したＣｅｌｌ Ｃｏｕｎｔｉｎｇ Ｋｉｔ－８（株式会社同仁化学研究所製）溶液 １５０μＬ／ｗｅｌｌを添加した。
（６）添加後のプレートを３７℃、５％ＣＯ２インキュベーター内に静置して適度に発色させた後、各ウェルの４５０ｎｍにおける吸光度を測定した。得られたデータを元に、コントロールに対する細胞賦活活性（％ ｏｆ ｃｏｎｔｒｏｌ）を下記式（１）に基づいて算出した。
Test 1: Evaluation of myotube activation effect (1) Mouse myoblast cell line (C2C12) was incubated in DMEM containing 10% (V/V) FBS using a 75 cm2 flask at 37°C in a 5% CO2 incubator. Cultured.
(2) Cells suspended by trypsin treatment were seeded from a 75 cm2 flask into each well of a collagen-coated 96-well plate at a cell density of 5000 cells/well.
(3) After culturing to confluence in a 5% CO2 incubator at 37°C, the cells were cultured in a differentiation induction medium for 5 days.
(4) 100 μL of each medium containing the test substance (Tables 1 to 3) prepared at a predetermined concentration with serum-free DMEM containing 0.5% (V/V) DMSO was added and cultured for 24 hours.
(5) After removing the medium, each well was washed once with 150 μL/well of serum-free DMEM. Next, 150 μL/well of Cell Counting Kit-8 (manufactured by Dojindo Laboratories Co., Ltd.) solution diluted 30 times with serum-free DMEM was added.
(6) After adding the plate, the plate was placed in a 5% CO2 incubator at 37°C to allow appropriate color development, and then the absorbance of each well at 450 nm was measured. Based on the obtained data, cell activation activity (% of control) was calculated based on the following formula (1).
被験物質として以下のものを用いた。
・ＨＭＢ又はその塩として、ＨＭＢＣａ（試薬）を用いた。
・テルペンとして、コロソリン酸、ウルソール酸及びオレアノール酸（いずれも試薬）を用いた。
The following were used as test substances.
- HMBCa (reagent) was used as HMB or its salt.
- As terpenes, corosolic acid, ursolic acid, and oleanolic acid (all reagents) were used.
図１～３に筋管細胞賦活作用の測定結果を示す。数値は、大きいほど筋管細胞賦活活性が高いことを示す。 Figures 1 to 3 show the results of measuring the myotube activation effect. The larger the value, the higher the myotube activation activity.
図１～３に示すように、ＨＭＢＣａ及びテルペンを用いた本発明の組成物は、各素材単独の場合に比して、優れた筋管細胞賦活作用を示した。したがって、本発明の組成物は優れた筋肉増強効果を有することがわかる。 As shown in FIGS. 1 to 3, the composition of the present invention using HMBCa and terpene showed superior myotube cell activating effect compared to the case of each material alone. Therefore, it can be seen that the composition of the present invention has an excellent muscle strengthening effect.
［実施例２］
試験２：ｐ－ｍＴＯＲタンパク質発現の評価
７週齢の雄性Ｗｉｓｔａｒ系ラットを５日以上訓化後、体重値に基づいて群分けした。試験開始日から２９日間、各群に対応した被験物質（表４）を連日で強制経口投与し、試験２９日目の被験物質投与後に絶食させた。１２－１８時間の絶食後、ペントバルビタールナトリウムの麻酔下にて開腹、下大静脈から採血を行った。採血終了後に下大静脈を鋏で切開し放血させることで安楽死させ、氷冷下で長趾伸筋を採取した。長趾伸筋肉中のｐ－ｍＴＯＲおよび内部標準としてβ－ｔｕｂｕｌｉｎのタンパク質発現量を測定した。
[Example 2]
Test 2: Evaluation of p-mTOR protein expression
After 7-week-old male Wistar rats were trained for 5 days or more, they were divided into groups based on body weight values. For 29 days from the start of the test, the test substance (Table 4) corresponding to each group was orally administered by force every day, and after the test substance was administered on the 29th day of the test, the animals were made to fast. After fasting for 12 to 18 hours, laparotomy was performed under anesthesia with pentobarbital sodium, and blood was collected from the inferior vena cava. After blood collection, the animal was euthanized by incising the inferior vena cava with scissors to exsanguinate blood, and the extensor digitorum longus muscle was collected under ice-cooling. The protein expression levels of p-mTOR and β-tubulin as an internal standard in the extensor digitorum longus muscle were measured.
ｐ－ｍＴＯＲおよびβ－ｔｕｂｕｌｉｎタンパク質発現量の測定は、以下の要領で行った。
長趾伸筋を、ＲＩＰＡバッファー（Ｔｈｅｒｍｏ）中でビーズショッカーを用いて破砕し、タンパク抽出液を得た。ウエスタンブロッティング法によってタンパク抽出液中のｐ－ｍＴＯＲおよびβ－ｔｕｂｕｌｉｎのタンパク質発現を解析した。β－ｔｕｂｕｌｉｎを内部標準としてｐ－ｍＴＯＲタンパク質量を補正し、ｃｏｎｔｒｏｌに対する相対的なｐ－ｍＴＯＲタンパク質発現量を算出した。
The expression levels of p-mTOR and β-tubulin proteins were measured as follows.
Extensor digitorum longus muscle was crushed using a bead shocker in RIPA buffer (Thermo) to obtain a protein extract. The protein expression of p-mTOR and β-tubulin in the protein extract was analyzed by Western blotting. The p-mTOR protein amount was corrected using β-tubulin as an internal standard, and the p-mTOR protein expression amount relative to control was calculated.
被験物質として以下のものを用いた。
・ＨＭＢ又はその塩として、ＨＭＢＣａの市販品を用いた。
・コロソリン酸として、バナバ葉の含水エタノール抽出物の乾燥粉末を用いた。コロソリン酸の含有量を高速液体クロマトグラフィー法で分析したところ、コロソリン酸含有量は９％であった。
なお、被験物質は純水に溶解、または十分に懸濁させたものを使用した。
The following were used as test substances.
- A commercially available product of HMBCa was used as HMB or its salt.
- Dry powder of a hydrous ethanol extract of banaba leaves was used as corosolic acid. When the content of corosolic acid was analyzed by high performance liquid chromatography, the content of corosolic acid was 9%.
The test substance used was dissolved or sufficiently suspended in pure water.
図４にｐ－ｍＴＯＲタンパク質発現量の相対値を示す。数値は、大きいほどｐ－ｍＴＯＲタンパク質発現が高いことを示す。 Figure 4 shows the relative values of p-mTOR protein expression levels. Higher values indicate higher p-mTOR protein expression.
ｐ－ｍＴＯＲは筋タンパク質の合成に関与し、これが増加することで筋肉量を増大させることが知られている。図４に示すように、ＨＭＢＣａ及びコロソリン酸を用いた本発明の組成物を投与した際のｐ－ｍＴＯＲタンパク質発現量は、各素材単独の場合と比較して非常に高く、各素材からは想定し得ない発現量を示した。また、ＨＭＢＣａを単独で高濃度投与した場合の発現量（投与量：３２０ｍｇ／ｋｇ、タンパク質発現量相対値：０．８７）と比較しても、高いｐ－ｍＴＯＲタンパク質発現を示した。したがって、本発明の組成物は優れた筋肉増強効果を有することがわかる。また、筋肉量の増加により基礎代謝量が向上するため、優れた抗肥満効果、特に体脂肪低減効果が期待できる。 It is known that p-mTOR is involved in the synthesis of muscle proteins, and an increase in this increases muscle mass. As shown in Figure 4, the expression level of p-mTOR protein when administering the composition of the present invention using HMBCa and corosolic acid was very high compared to the case of each material alone; The expression level was unprecedented. Furthermore, high p-mTOR protein expression was also shown when compared to the expression level when HMBCa was administered alone at a high concentration (dose: 320 mg/kg, protein expression level relative value: 0.87). Therefore, it can be seen that the composition of the present invention has an excellent muscle strengthening effect. In addition, since the basal metabolic rate improves due to the increase in muscle mass, an excellent anti-obesity effect, especially an effect of reducing body fat, can be expected.
［実施例５］
下記成分からなる錠剤（１粒あたり２５０ｍｇ）を製造した。得られた錠剤を１日あたり４粒摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 5]
Tablets (250 mg per tablet) consisting of the following ingredients were manufactured. By taking four of the resulting tablets per day, excellent muscle-building and anti-obesity effects can be obtained.
［実施例６］
下記成分からなる錠剤（１粒あたり２５０ｍｇ）を製造した。得られた錠剤を１日１回、１回あたり４粒摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 6]
Tablets (250 mg per tablet) consisting of the following ingredients were manufactured. By taking four of the resulting tablets once a day, excellent muscle-building and anti-obesity effects can be obtained.
［実施例７］
下記成分からなる錠剤（１粒あたり２００ｍｇ）を製造した。得られた錠剤を１日２回、１回あたり４粒（合計８粒）摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 7]
Tablets (200 mg per tablet) consisting of the following ingredients were manufactured. By taking the resulting tablets twice a day, 4 tablets each time (8 tablets in total), excellent muscle-building and anti-obesity effects can be obtained.
［実施例８］
下記成分からなる錠剤（１粒あたり２５０ｍｇ）を製造した。得られた錠剤を１日１回、１回あたり５粒摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 8]
Tablets (250 mg per tablet) consisting of the following ingredients were manufactured. By taking five of the resulting tablets once a day, excellent muscle-building and anti-obesity effects can be obtained.
［実施例９］
下記成分からなる錠剤（１粒あたり２５０ｍｇ）を製造した。得られた錠剤を１日あたり４粒摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 9]
Tablets (250 mg per tablet) consisting of the following ingredients were manufactured. By taking four of the resulting tablets per day, excellent muscle-building and anti-obesity effects can be obtained.
［実施例１０］
下記成分からなる錠剤（１粒あたり２５０ｍｇ）を製造した。得られた錠剤を１日１回、１回あたり４粒摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 10]
Tablets (250 mg per tablet) consisting of the following ingredients were manufactured. By taking four of the resulting tablets once a day, excellent muscle-building and anti-obesity effects can be obtained.
［実施例１１］
下記成分からなる錠剤（１粒あたり２００ｍｇ）を製造した。得られた錠剤を１日２回、１回あたり４粒（合計８粒）摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 11]
Tablets (200 mg per tablet) consisting of the following ingredients were manufactured. By taking the resulting tablets twice a day, 4 tablets each time (8 tablets in total), excellent muscle-building and anti-obesity effects can be obtained.
［実施例１２］
下記成分からなる錠剤（１粒あたり２５０ｍｇ）を製造した。得られた錠剤を１日あたり４粒摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 12]
Tablets (250 mg per tablet) consisting of the following ingredients were manufactured. By taking four of the resulting tablets per day, excellent muscle-building and anti-obesity effects can be obtained.
［実施例１３］
下記成分からなる錠剤（１粒あたり２５０ｍｇ）を製造した。得られた錠剤を１日１回、１回あたり４粒摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 13]
Tablets (250 mg per tablet) consisting of the following ingredients were manufactured. By taking four of the resulting tablets once a day, excellent muscle-building and anti-obesity effects can be obtained.
［実施例１４］
下記成分からなる錠剤（１粒あたり２００ｍｇ）を製造した。得られた錠剤を１日２回、１回あたり４粒（合計８粒）摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 14]
Tablets (200 mg per tablet) consisting of the following ingredients were manufactured. By taking the resulting tablets twice a day, 4 tablets each time (8 tablets in total), excellent muscle-building and anti-obesity effects can be obtained.
［実施例１５］
下記成分からなるチュアブル錠剤（１粒あたり７００ｍｇ）を製造した。得られたチュアブル錠剤を１日あたり２粒摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 15]
Chewable tablets (700 mg per tablet) consisting of the following ingredients were manufactured. By taking two of the resulting chewable tablets per day, excellent muscle-building and anti-obesity effects can be obtained.
［実施例１６］
下記成分からなるチュアブル錠剤（１粒あたり１０００ｍｇ）を製造した。得られたチュアブル錠剤を１日３回、１回あたり２粒（合計６粒）摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 16]
Chewable tablets (1000 mg per tablet) consisting of the following ingredients were manufactured. By taking the resulting chewable tablets three times a day, two tablets each time (six tablets in total), excellent muscle-building and anti-obesity effects can be obtained.
［実施例１７］
下記混合物をハードカプセルに封入し、カプセル剤（１粒あたり３００ｍｇ）を製造した。得られたカプセル剤を１日あたり４粒摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 17]
The following mixture was encapsulated in hard capsules to produce capsules (300 mg per capsule). By taking four of the resulting capsules per day, excellent muscle-building and anti-obesity effects can be obtained.
［実施例１８］
下記混合物をハードカプセルに封入し、カプセル剤（１粒あたり２５０ｍｇ）を製造した。得られたカプセル剤を１日２回、１回あたり３粒（合計６粒）摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 18]
The following mixture was encapsulated in hard capsules to produce capsules (250 mg per capsule). By taking the resulting capsules twice a day, 3 capsules each time (6 capsules in total), excellent muscle-building and anti-obesity effects can be obtained.
［実施例１９］
下記成分からなる顆粒剤（１包あたり３０００ｍｇ）を製造した。得られた顆粒剤を１日２回、１回あたり１包を水に懸濁して摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 19]
Granules (3000 mg per package) consisting of the following ingredients were produced. By ingesting the resulting granules twice a day, one packet per time suspended in water, excellent muscle-building and anti-obesity effects can be obtained.
［実施例２０］
下記成分からなる顆粒剤（１包あたり２０００ｍｇ）を製造した。得られた顆粒剤を１日２回、１回あたり１包を摂取することで、優れた筋肉増強効果や抗肥満効果が得られる。
[Example 20]
Granules (2000 mg per package) consisting of the following ingredients were produced. By taking one packet of the obtained granules twice a day, excellent muscle-building and anti-obesity effects can be obtained.
本発明の経口組成物は、筋肉増強効果、抗肥満効果を有することから、本発明の産業上の有用性は高い。 Since the oral composition of the present invention has a muscle-building effect and an anti-obesity effect, the industrial utility of the present invention is high.
Claims (2)
（１）３－ヒドロキシ－３－メチル酪酸又はその塩。
（２）オレアノール酸。 An oral composition for activating myotube cells (excluding those containing elastin), which contains the following (1) and (2).
(1) 3-hydroxy-3-methylbutyric acid or its salt.
(2) Oleanolic acid.
(2) The oral composition for activating myotube cells according to claim 1, which displays oleanolic acid as an active ingredient.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017215519 | 2017-11-08 | ||
| JP2017215519 | 2017-11-08 | ||
| JP2018121380A JP7100882B2 (en) | 2017-11-08 | 2018-06-26 | Oral composition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018121380A Division JP7100882B2 (en) | 2017-11-08 | 2018-06-26 | Oral composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022130534A JP2022130534A (en) | 2022-09-06 |
| JP7373869B2 true JP7373869B2 (en) | 2023-11-06 |
Family
ID=66762324
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018121380A Active JP7100882B2 (en) | 2017-11-08 | 2018-06-26 | Oral composition |
| JP2022100942A Active JP7373869B2 (en) | 2017-11-08 | 2022-06-23 | Oral composition |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018121380A Active JP7100882B2 (en) | 2017-11-08 | 2018-06-26 | Oral composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP7100882B2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7100882B2 (en) | 2017-11-08 | 2022-07-14 | 株式会社東洋新薬 | Oral composition |
| JP2020195286A (en) * | 2019-05-31 | 2020-12-10 | 株式会社東洋新薬 | Oral composition |
| JP6883364B1 (en) * | 2020-05-25 | 2021-06-09 | 株式会社東洋新薬 | Oral compositions, muscle-building compositions and anti-obesity compositions |
| KR102645399B1 (en) * | 2022-07-25 | 2024-03-11 | 코스맥스엔에스 주식회사 | Composition for improving muscular function, or preventing, ameliorating or treating muscle disease comprising euscaphic acid |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006034586A1 (en) | 2004-09-29 | 2006-04-06 | Aplodan Formulations Ltd. | Nutritional composition for promoting muscle performance and acting as hydrogen (h+) blocker |
| JP2013517806A (en) | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | Nutritional powder containing spray-dried HMB |
| WO2014099904A1 (en) | 2012-12-17 | 2014-06-26 | Abbott Laboratories | Methods for enhancing motor function, enhancing functional status and mitigating muscle weakness in a subject |
| JP2019085392A (en) | 2017-11-08 | 2019-06-06 | 株式会社東洋新薬 | Oral composition |
-
2018
- 2018-06-26 JP JP2018121380A patent/JP7100882B2/en active Active
-
2022
- 2022-06-23 JP JP2022100942A patent/JP7373869B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006034586A1 (en) | 2004-09-29 | 2006-04-06 | Aplodan Formulations Ltd. | Nutritional composition for promoting muscle performance and acting as hydrogen (h+) blocker |
| JP2013517806A (en) | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | Nutritional powder containing spray-dried HMB |
| WO2014099904A1 (en) | 2012-12-17 | 2014-06-26 | Abbott Laboratories | Methods for enhancing motor function, enhancing functional status and mitigating muscle weakness in a subject |
| JP2019085392A (en) | 2017-11-08 | 2019-06-06 | 株式会社東洋新薬 | Oral composition |
Non-Patent Citations (5)
| Title |
|---|
| Frontiers in pharmacology，2017年07月17日，Vol.8, No.468，pp.1-13 |
| INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE，2015年，Vol. 35, Issue 3，Pages 755-762 |
| J. Agric. Food. Chem.，2007年，55，Pages 4366-4370 |
| おなかカンパニーＲＯＴＴＳウェブサイト，2018年01月10日，インターネットアーカイブ閲覧 URL: https://web.archive.org/web/20180110064238/http://rotts.co.jp:80/product/s021/1069 |
| 日本健康素材株式会社技術資料，2016年，http://nihon-hm.co.jp/wp-content/uploads/2016/02/%E3%82%A2%E3%83%83%E3%83%97%E3%83%AB%E3%83%86%E3%83%AB%E3%83%9A%E3%83%B320160817%E6%94%B9%E5%AE%9A.pdf |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019085392A (en) | 2019-06-06 |
| JP7100882B2 (en) | 2022-07-14 |
| JP2022130534A (en) | 2022-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7373869B2 (en) | Oral composition | |
| US20140050810A1 (en) | Anti-obesity composition comprising lycium chinensis leaf extract and betaine as active ingredient | |
| JP5888574B1 (en) | Blood flow improver | |
| JP6584270B2 (en) | Blood flow improving composition | |
| JP2023075284A (en) | oral composition | |
| JP2022173374A (en) | oral composition | |
| JP2015017044A (en) | Agent for fat accumulation inhibition and/or fat accumulation amount reduction | |
| JP6906830B1 (en) | Oral compositions, muscle-building compositions and anti-obesity compositions | |
| JP2019054791A (en) | Fatigue improving composition | |
| JP6742575B2 (en) | Joint function improving composition | |
| JP6646369B2 (en) | Anti-fatigue agent | |
| JP6838752B2 (en) | Blood flow improving composition | |
| JP7117763B2 (en) | oral composition | |
| JP2020063216A (en) | Oral composition | |
| JP6883364B1 (en) | Oral compositions, muscle-building compositions and anti-obesity compositions | |
| JP6829487B2 (en) | Anti-fatigue | |
| JP2022173468A (en) | Bloodstream ameliorating composition | |
| JP6744673B2 (en) | Joint function improving composition | |
| JP7058407B2 (en) | Oral composition | |
| JP2021185767A (en) | Composition containing peat | |
| JP2021042152A (en) | Phosphodiesterase 5a1 activity inhibitor, muscle relaxation or contraction inhibitor, and dysuria preventive or improver | |
| JP2021013326A (en) | Composition comprising oleanane-type triterpene for preventing or improving physical fatigue or fatigue feeling | |
| JP2020195286A (en) | Oral composition | |
| JP2014172901A (en) | Fat absorption inhibitor | |
| JP2022121730A (en) | Anti-fatigue agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220712 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220713 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230718 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230914 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231010 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231017 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7373869 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |